Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01078909 · ClinicalTrials.gov registry record · Phase 3
Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation
A Phase 3 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT01078909 is a Phase 3 study that has completed, run by Penn State University. The registered enrollment target is 125 participants.
The verdict
NCT01078909, a Phase 3 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several inflammatory markers.
Interventions
- BIOLOGICAL Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2011-10 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01078909
The ClinicalTrials.gov registry entry for NCT01078909 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Penn State University, which has 219 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) is the first listed.
NCT01078909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01078909 about?
NCT01078909 is a clinical study titled "Dose Response Effects of Marine Omega-3 Fatty Acids on Inflammation". The purpose of this study is to determine the lowest effective dose of EPA + DHA (300, 600, 900 and 1,800 mg/day delivered as fish oil supplements) that significantly attenuates the inflammatory response to in vivo and ex vivo endotoxin challenge as measured by the production over time of several in...
What is the current status of trial NCT01078909?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2011-10. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01078909?
The interventions under investigation include: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01078909?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.